AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05838911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group Chest physical therapy
Description: The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
Study NCT05074771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC intellicare
Description: ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
Study NCT04843982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
Study NCT04205136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: If tolerated and serum potassium \<5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is >5.0 but less than 5.5 or creatinine >4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
Study NCT04205136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
Study NCT06402214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lombard test
Description: In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
Study NCT06402214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lombard test
Description: In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
Study NCT05153785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
Study NCT05153785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT06345326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block
Description: The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.
Study NCT05652790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Rehabilitation Programme
Description: The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy
Study NCT05652790 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: Standard care received at usual NHS facility
Study NCT04784455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nomacopan (rVA576)
Description: The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
Study NCT05367206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260mg/m2 q3w \*2 circles
Study NCT05367206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 q3w \* 2 circles
Study NCT05101915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: Inhaled IMP delivered via nebulisation
Study NCT05010785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and alveolar ridge splitting with GBR and i-PRF
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
Study NCT05010785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement and alveolar ridge splitting with GBR
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
Study NCT05832229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
Study NCT05832229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
Study NCT05776979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given by vein over about 75 minutes
Study NCT05776979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given by PO
Study NCT06441825 — intervention group
Intervention type: OTHER
Intervention: Increased multimodal observation including digital monitoring
Description: Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers
Study NCT06176820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Gel
Description: Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
Study NCT06176820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal lubricant
Description: Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
Study NCT04734535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST™ Bellows
Description: Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
Study NCT04734535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable gelatin sponge with thrombin
Description: Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
Study NCT05699785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma inflammatory markers
Description: Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
Study NCT05699785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Description: Evolution of CD4/CD8 ratio
Study NCT06249321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX plus IMRT
Description: Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
Study NCT04230668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy with Suicide Risk Management
Description: CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
Study NCT04230668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual with Suicide Rick Management
Description: In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
Study NCT04823364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurotransmitters evaluation by MRS
Description: Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
Study NCT06172114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using sticky bone
Description: In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
Study NCT06172114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using sticky bone
Description: In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
Study NCT06348264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
Study NCT06348264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
Study NCT06360952 — intervention group
Intervention type: DEVICE
Intervention: Tasso+ CBC
Description: Novel blood collection device
Study NCT05925062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QActual
Description: QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
Study NCT04811664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine
Description: A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
Study NCT05988333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational Family Intervention
Description: Supportive intervention administered to families with a member affected by MDD
Study NCT05988333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative intervention
Description: Informative intervention administered to families with a member affected by MDD
Study NCT05461937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Getting things done after stroke
Description: A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
Study NCT05461937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke psychoeducation
Description: A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
Study NCT04658654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: chronic intervention (24 weeks): roflumilast capsule
Study NCT04658654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Pill with inactive ingredients to mimic same appearance of roflumilast capsule
Study NCT05097209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
Study NCT05097209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
Study NCT05097209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
Study NCT05097209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
Study NCT05097209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
Study NCT05097209 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
Study NCT05097209 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
Study NCT05097209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent cisplatin
Description: Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Study NCT06339749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).
Study NCT05732558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system
Description: The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
Study NCT06339749 — intervention group
Intervention type: OTHER
Intervention: Clinical protocols for preeclampsia risk screening
Description: In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester.
Study NCT05082207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
Study NCT05082207 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: a deflated cuff placed on the upper arm for 30 min
Study NCT04680637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin Alfa
Description: Administered as a subcutaneous (SC) injection.
Study NCT05052697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mIRV
Description: Intramuscular injection
Study NCT04680637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a subcutaneous (SC) injection.
Study NCT04680637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
Study NCT04680637 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
Study NCT05052697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bIRV AB
Description: Intramuscular injection
Study NCT05052697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV
Description: Intramuscular injection
Study NCT05052697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Intramuscular injection
Study NCT05052697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bIRV AA
Description: Intramuscular injection
Study NCT05052697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bIRV BB
Description: Intramuscular injection
Study NCT03280316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: patients with SVMs receive surgery
Study NCT03280316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral neuromodulation
Description: sacral neuromodulation (SNM) with InterStimTM
Study NCT03280316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxin A injection
Description: BOTOX
Study NCT03280316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M receptor antagonist
Description: Tolterodine
Study NCT05368909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sleep Supplement
Description: Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
Study NCT05368909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo product
Study NCT05032729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trypophan, Theanine and 5'AMP
Description: 250 ml beverage consumed at 21:00 hours
Study NCT05032729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
Study NCT05345756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral protraction device
Description: Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
Study NCT05345756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraoral protraction device
Description: Facemask which is an extraoral appliance used for maxillary protraction